SCHEMBL2830596

SCHEMBL2830596

CC(=O)N1c2ccccc2C[C@H]1C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.66
ACE P12821 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2824813 1.00 NOTUM (0.66) NOTUMACE
SCHEMBL2824809 1.00 NOTUM (0.66) NOTUMACE
SCHEMBL31207052 1.00 NOTUM (0.66) NOTUMACE
SCHEMBL30745240 1.00 NOTUM (0.66) NOTUMACE
SCHEMBL29697839 1.00 NOTUM (0.66) NOTUMACE
SCHEMBL2827480 0.98 NOTUM (0.64) NOTUMACE
SCHEMBL2827485 0.98 NOTUM (0.64) NOTUMACE
SCHEMBL2827489 0.98 NOTUM (0.64) NOTUMACE
SCHEMBL16350248 0.88 NOTUM (0.68) NOTUMACE
SCHEMBL4707127 0.88 NOTUM (0.68) NOTUMACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006053440-A1 NEW PROCESSES FOR THE PREPARATION OF OPTICALLY PURE INDOLINE-2-CARBOXYLIC ACID AND N-ACETYL-INDOLINE-2-CARBOXYLIC ACID APOTEX PHARMACHEM INC. (CA) 2006-05-26 WO claimed
JP-61030572-A None JP disclosed
US-20100330625-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE INDOLINE-2-CARBOXYLIC ACID OR DERIVATIVE THEREOF MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2010-12-30 US disclosed
EP-2251431-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE INDOLINE-2-CARBOXYLIC ACID OR DERIVATIVE THEREOF Mitsubishi Gas Chemical Company, Inc. (JP) 2010-11-17 EP disclosed
US-20090253932-A1 Resolution of Racemic Organic Acids with (1S, 4S)-4[3,4-Dichlorophenyl]-1,2,3,4-Tetrahydro-N-Methyl-1-Naphthaloneamine MATRIX LABORATORIES LTD (IN) 2009-10-08 US disclosed
WO-2006053440-A1 NEW PROCESSES FOR THE PREPARATION OF OPTICALLY PURE INDOLINE-2-CARBOXYLIC ACID AND N-ACETYL-INDOLINE-2-CARBOXYLIC ACID APOTEX PHARMACHEM INC. (CA) 2006-05-26 WO disclosed
WO-2006053440-A1 NEW PROCESSES FOR THE PREPARATION OF OPTICALLY PURE INDOLINE-2-CARBOXYLIC ACID AND N-ACETYL-INDOLINE-2-CARBOXYLIC ACID APOTEX PHARMACHEM INC. (CA) 2006-05-26 WO disclosed
US-7034051-B2 Fused bicyclic carboxamide derivatives and methods of their use ADOLOR CORPORATION (US) 2006-04-25 US disclosed
WO-2005023799-A1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2005-03-17 WO disclosed
US-20050054630-A1 Fused bicyclic carboxamide derivatives and methods of their use CUBIST PHARMACEUTICALS, INC. 2005-03-10 US disclosed
EP-0937714-A1 Process for the preparation of an optically active indoline-2-carboxylic acid or derivative thereof DSM N.V. (NL) 1999-08-25 EP disclosed
EP-0838448-A1 Process for the separation of a mixture of enantiomers DSM N.V. (NL) 1998-04-29 EP disclosed
US-4665087-A ANGIOTENSIN-CONVERTING ENZYME INHIBITORS CIBA-GEIGY CORPORATION (US) 1987-05-12 US disclosed
US-4599357-A 1-mercaptoalkanoylindoline-2-carboxylic acids CIBA-GEIGY CORPORATION (US) 1986-07-08 US disclosed
JP-S6130572-A METHOD OF OPTICAL RESOLUTION OF (RS)-1-ACETYL-INDOLINE-2-CARBOXYLIC ACID DAINIPPON PHARMACEUT CO LTD 1986-02-12 JP disclosed
US-4568489-A ANGIOTENSIN AND ENKEPHALINASE INHIBITORS; HYPOTENSIVE AGENT, ANALGESIC E. R. SQUIBB & SONS, INC. (US) 1986-02-04 US disclosed
US-4479963-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1984-10-30 US disclosed
EP-0105919-A1 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES. CIBA GEIGY AG (CH) 1984-04-25 EP disclosed
WO-1983003828-A1 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES CIBA-GEIGY AG (CH) 1983-11-10 WO disclosed
US-4374847-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1983-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253932-A1 Resolution of Racemic Organic Acids with (1S, 4S)-4[3,4-Dichlorophenyl]-1,2,3,4-Tetrahydro-N-Methyl-1-Naphthaloneamine HTR4, OXER1, CYP2S1 NOTUM 1699/4885ACE 3542/4885
US-20050054630-A1 Fused bicyclic carboxamide derivatives and methods of their use PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 NOTUM 407/4885ACE 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.